A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions

• DOI: 10.1016/j.ctarc.2022.100671
• Publication Date: 2022-12-11T14:41:21Z
• Authors: Asma Munir; Simon Holt; Anita Marie Huws; Sohail Khan; Dr Mark Davies; Saira Khawaja; Yousef Sharaiha
• Keywords: Adjuvant Chemotherapy; Distant metastasis

To explore the long-term outcome of patients who underwent Oncotype DX® testing. The relationship between RS, adjuvant treatments received, and clinical outcomes across entire range RS results are reported.10-year Kaplan-Meier estimates for distant recurrence/BC-specific survival (BCSS) in this cohort. analysis included 439 patients. follow-up time ranged from 14 to 142 months. All analyses were performed using SPSS v20.More than half had low (<18) (55.6%) 15.3% ≥ 31. Chemotherapy use was consistent with 4.4%, 7.1%, 28.0%, 71.4% 91.0% receiving chemotherapy < 11, 11-17, 18-25, 26-30, ≥31, respectively. overall rate 27.6%. Distant metastasis free (DMFS) differed significantly (P 0.001) groups 10 year DMFS rates 99% (SE +/- 0.01) RS<11, 97% 0.03) 0.02) 85% 0.1) 26-30 74% 0.08) 31 group. Ten breast cancer specific also groups; risk 100% (no deaths reported first years) 95% 94% 0.04) 93% 0.07) 79% group.Use DX does guide treatment decisions correlates BCSS disease-free ER positive, Her2 negative, early-stage, node negative